Cargando…

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis

INTRODUCTION: Despite the increased availability of disease-modifying therapies (DMTs) for treating relapsing-remitting multiple sclerosis (RR-MS), only a few studies have evaluated DMT-associated brain functional changes. METHODS: We investigated whether significant resting-state functional connect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piervincenzi, Claudia, Sbardella, Emilia, Altieri, Marta, Ianniello, Antonio, Pantano, Patrizia, Pozzilli, Carlo, Petsas, Nikolaos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857342/ https://www.ncbi.nlm.nih.gov/pubmed/35119678 http://dx.doi.org/10.1007/s40120-022-00328-w

Ejemplares similares

Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients
por: Sbardella, Emilia, et al.
Publicado: (2013)

DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications
por: Sbardella, Emilia, et al.
Publicado: (2013)

Evidence of Impaired Brain Activity Balance after Passive Sensorimotor Stimulation in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2013)

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients
por: Piervincenzi, Claudia, et al.
Publicado: (2021)

The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence
por: Tomassini, Valentina, et al.
Publicado: (2016)

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2019)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

The Role of fMRI to Assess Plasticity of the Motor System in MS
por: Pantano, Patrizia, et al.
Publicado: (2015)

Resting-State fMRI in MS: General Concepts and Brief Overview of Its Application
por: Sbardella, Emilia, et al.
Publicado: (2015)

Parkinsonism Is Associated with Altered SMA-Basal Ganglia Structural and Functional Connectivity in Frontotemporal Degeneration
por: Piervincenzi, Claudia, et al.
Publicado: (2023)

A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2020)

Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models
por: Kihara, Yasuyuki, et al.
Publicado: (2015)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2021)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques
por: Taloni, Alessandro, et al.
Publicado: (2022)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis
por: Tommasin, Silvia, et al.
Publicado: (2021)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis
por: Guerriero, Claudia, et al.
Publicado: (2022)

Neuroimaging markers of Alice in Wonderland syndrome in patients with migraine with aura
por: Mastria, Giulio, et al.
Publicado: (2023)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?
por: Belvisi, Daniele, et al.
Publicado: (2022)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Advances in spinal cord imaging in multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2019)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
por: Zinger, Nicole, et al.
Publicado: (2022)

Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability
por: Tommasin, Silvia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q4qib0hkhv03gd0j47mf2fqu0u